The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Full approval will depend on verification of clinical benefit in a confirmatory trial
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Subscribe To Our Newsletter & Stay Updated
